ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology granted an inducement stock option to purchase 500,000 shares to Michael Listgarten, its new General Counsel, in connection with the commencement of his employment. The option has an exercise price of $2.20 per share — equal to the closing price on the June 29, 2026 grant date — with 25% vesting after one year and the remainder vesting monthly over the following three years.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.